Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease

Next Previous
X
Search
Trial Profile

A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deutetrabenazine (Primary)
  • Indications Chorea; Huntington's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms First-HD
  • Sponsors Auspex Pharmaceuticals; Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries

    • Most Recent Events

    • 22 Apr 2021 Results of pooled analysis of two pivotal studies First-HD and ARC-HD assessing the safety of deutetrabenazine in treating tardive dyskinesia and chorea associated with Huntingtons disease, presented at the 73rd Annual Meeting of the American Academy of Neurology.
    • 15 Apr 2021 According to a Teva Pharmaceutical Industries media release, data from First-HD pivotal trial and long-term open label extension trial (ARC-HD) will be presented at the upcoming 2021 American Academy of Neurology (AAN) Virtual Annual Meeting.
    • 03 Apr 2017 The U.S. Food and Drug Administration (FDA) has approved AUSTEDO (deutetrabenazine) tablets for the treatment of chorea associated with Huntingtons disease, based on the data from this trial, according to Teva Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top